MONOPAR THERAPEUTICS (MNPR): Price and Financial Metrics

MONOPAR THERAPEUTICS (MNPR): $0.65

0.02 (+2.85%)

POWR Rating

Component Grades

Momentum

D

Stability

D

Sentiment

Quality

C

Add MNPR to Watchlist
Sign Up

Industry: Biotech

Industry

F

Ranked

#135 of 359

in industry

MNPR Price/Volume Stats

Current price $0.65 52-week high $1.75
Prev. close $0.63 52-week low $0.27
Day low $0.61 Volume 85,900
Day high $0.66 Avg. volume 4,388,737
50-day MA $0.74 Dividend yield N/A
200-day MA $0.57 Market Cap 11.35M

MNPR Stock Price Chart Interactive Chart >


MONOPAR THERAPEUTICS (MNPR) Company Bio


Monopar Therapeutics, Inc. engages in developing orphan oncology drugs. The company was founded by Chandler D. Robinson, Christopher M. Starr and Andrew P. Mazar in December 2014 and is headquartered in Wilmette, IL.


MNPR Latest News Stream


Event/Time News Detail
Loading, please wait...

MNPR Latest Social Stream


Loading social stream, please wait...

View Full MNPR Social Stream

Latest MNPR News From Around the Web

Below are the latest news stories about MONOPAR THERAPEUTICS that investors may wish to consider to help them evaluate MNPR as an investment opportunity.

Monopar Therapeutics Inc Reports Q3 2023 Financial Results and Progress in Clinical Programs

Key Developments and Financial Highlights for Investors

Yahoo | November 9, 2023

Monopar Therapeutics Reports Third Quarter 2023 Financial Results and Recent Developments

MNPR-101 Radiopharma Program to Enter First-in-Human Studies Potentially As Early As December of This Year Camsirubicin Phase 1b Trial Efficacy and Safety Data Highlighted at the 2023 CTOS Annual MeetingWILMETTE, Ill., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Monopar or the Company) (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing innovative treatments for cancer patients, today announced third quarter 2023 financial results and summarized rece

Yahoo | November 9, 2023

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday

It's time to dive into the biggest pre-market stock movers for Friday with all the shares investors will want to keep an eye on today!

William White on InvestorPlace | November 3, 2023

Monopar Presents Data Showing Tumor Reduction Benefit of Camsirubicin from Ongoing Phase 1b at the 2023 Connective Tissue Oncology Society (CTOS) Annual Meeting

WILMETTE, Ill., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients, will present data from its ongoing Phase 1b open-label, dose-escalating clinical trial of camsirubicin in patients with advanced soft tissue sarcoma (ASTS) later today at the 2023 Connective Tissue Oncology Society (CTOS) Annual Meeting, whic

Yahoo | November 1, 2023

Monopar to Participate in the Roth MKM 2023 Healthcare Opportunities Conference

WILMETTE, Ill., Oct. 10, 2023 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing innovative treatments for cancer patients, today announced that Andrew J. Cittadine, Monopar’s Chief Operating Officer, will present at the Roth MKM 2023 Healthcare Opportunities Conference. Presentation Details: Date: October 12, 2023Time: 12:15 p.m. (ET)Location: The Yale Club, New York City, New York https://www.roth.com/conferences/upcom

Yahoo | October 10, 2023

Read More 'MNPR' Stories Here

MNPR Price Returns

1-mo -8.45%
3-mo 75.68%
6-mo 41.30%
1-year -41.44%
3-year -88.91%
5-year N/A
YTD 91.06%
2023 -85.65%
2022 -26.17%
2021 -47.55%
2020 -63.13%
2019 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!